TIDMERGO

RNS Number : 6032Q

Ergomed plc

01 March 2021

PRESS RELEASE

Total Voting Rights

Guildford, UK - 1 March 2021 : In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 28 February 2021 consisted of 48,746,109 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 1483 402 
                                                                         975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
 
 Numis Securities Limited                          Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for          Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Matthew Neal                    ergomed@consilium-comms.com 
 Angela Gray / Olivia Manser 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRTPMPTMTATBTB

(END) Dow Jones Newswires

March 01, 2021 02:00 ET (07:00 GMT)